Safety of oral ibandronate in the treatment of bone metastases from breast cancer: Long-term follow-up experience

Clinical Drug Investigation

Volumn 26, Issue 1, 2006, Pages 43-48

  McLachlan, Sue Anne ^a   Cameron, David ^b   Murray, Robin ^c   Tripathy, Debu ^d   Bergström, Bengt ^e  

^a ST VINCENT S HOSPITAL   (Australia)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBANDRONIC ACID;

ADULT; ARTICLE; ASCITES; BACKACHE; BONE PAIN; BRAIN INFARCTION; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPEPSIA; ENDOCRINE DISEASE; ESOPHAGITIS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOCALCEMIA; METABOLIC DISORDER; METASTASIS; MULTICENTER STUDY; MUSCULOSKELETAL SYSTEM MALFORMATION; NEUROTOXICITY; NUTRITIONAL DISORDER; PATIENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; CREATININE; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; MIDDLE AGED;

EID: 30744441403     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626010-00006     Document Type: Article

References (30)

1. Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 2000; 1: 43-51
2. Body JJ, editor. Tumor bone disease and osteoporosis in cancer patients. New York: Marcel Dekker, 2000
3. Coleman RE. Metastatic bone disease: clinical fractures, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-76
4. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434-7
5. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003; 41: E18
6. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-9
7. Novartis Pharma. Zometa® (zoledronic acid). Prescribing infor-mation
8. Novartis Pharma. Aredia® (pamidronate). Prescribing information
9. Major P, Lipton A, Berenson J, et al. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 2000; 88: 6-14
10. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65
11. Atula S, Powles T, Paterson A, et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 2003; 26: 661-71
12. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5
13. Body JJ, Diel IJ, Lichinitser M, et al. Intravenous ibandronic acid reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-405
14. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-7
15. Body JJ, Diel IJ, Bell R, et al. Oral Ibandronic acid improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111: 316-2
16. Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004; 15: 743-50
17. Cancer Therapy Evaluation Program, Common Toxicity Criteria Version 2.0, DCTD, NCI, NIH, DHHS [online]. 1999 Apr 30 Available from URL: http://ctep.cancer.gov/reporting/CTC-3test.html
18. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-24
19. Pecherstorfer M, Diel IJ, Bergström B. Long-term (4-year) safety of intravenous ibandronate in metastatic breast cancer: an open-label study [abstract]. Eur J Cancer Suppl 2004; 2: 130
20. Body JJ, Diel I, Tripathy D, et al. Impact of ibandronic acid on bone pain in patients with metastatic bone disease from breast cancer [abstract no. A-34]. Support Care Cancer 2003; 11: 395-6
21. Tripathy D, Pecherstorfer M, Bartl R, et al. Reduction in risk of skeletal events with ibandronic acid in the treatment of metastatic breast cancer [abstract no. A-152]. Support Care Cancer 2003; 11: 427
22. Navarro RP, Morrow T, Baran R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag Care Interface 2002; 15: 55-62
23. De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronic acid versus i.v. zoledronic acid and i.v. pamidronate in the treatment of metastatic bone disease in breast cancer [abstract no. 189P]. Ann Oncol 2004; 15 Suppl. 3: iii50
24. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869-76
25. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933-7
26. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427-30
27. Paterson AHG. Adjuvant bisphosphonate therapy: the future. Semin Oncol 2001; 28: 81-5
28. Diel IJ, Solomayer EF, Costa S, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63
29. Green JR. Antitumor effects of bisphosphonates. Cancer Suppl 2003; 97: 840-7
30. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509-17